Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela M Minassian

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
JCI Insight|January 24, 2023
Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccineCarolyn M Nielsen, Jordan R Barrett, Christine Davis, et al.
BMJ Open|November 22, 2011
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsAngela M Minassian, Rosalind Rowland, Natalie E R Beveridge, et al.
Frontiers in Immunology|August 2, 2021
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human TrialHans de Graaf, Ruth O Payne, Iona Taylor, et al.
Frontiers in Immunology|September 8, 2022
Repeat controlled human malaria infection of healthy UK adults with blood-stage <i>Plasmodium falciparum</i>: Safety and parasite growth dynamicsJo Salkeld, Yrene Themistocleous, Jordan R Barrett, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
Immunity|June 12, 2026
Analysis of monoclonal antibodies against the malaria invasion complex protein RIPR reveals the structural basis for synergistic antibody protectionBarnabas G Williams, Jordan R Barrett, Josefin Bartholdson Scott, et al.
The Lancet. Infectious Diseases|December 13, 2024
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in childrenHamtandi M Natama, Jo Salkeld, Athanase Somé, et al.
The Journal of Infection|June 18, 2023
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trialEimear Kelly, Melanie Greenland, Philip C S de Whalley, et al.
NPJ Vaccines|August 23, 2018
Production, quality control, stability, and potency of cGMP-produced <i>Plasmodium falciparum</i> RH5.1 protein vaccine expressed in <i>Drosophila</i> S2 cellsJing Jin, Richard D Tarrant, Emma J Bolam, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
JCI Insight|January 24, 2023
Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccineCarolyn M Nielsen, Jordan R Barrett, Christine Davis, et al.
BMJ Open|November 22, 2011
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsAngela M Minassian, Rosalind Rowland, Natalie E R Beveridge, et al.
Frontiers in Immunology|August 2, 2021
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human TrialHans de Graaf, Ruth O Payne, Iona Taylor, et al.
Frontiers in Immunology|September 8, 2022
Repeat controlled human malaria infection of healthy UK adults with blood-stage <i>Plasmodium falciparum</i>: Safety and parasite growth dynamicsJo Salkeld, Yrene Themistocleous, Jordan R Barrett, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
Immunity|June 12, 2026
Analysis of monoclonal antibodies against the malaria invasion complex protein RIPR reveals the structural basis for synergistic antibody protectionBarnabas G Williams, Jordan R Barrett, Josefin Bartholdson Scott, et al.
The Lancet. Infectious Diseases|December 13, 2024
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in childrenHamtandi M Natama, Jo Salkeld, Athanase Somé, et al.
The Journal of Infection|June 18, 2023
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trialEimear Kelly, Melanie Greenland, Philip C S de Whalley, et al.
NPJ Vaccines|August 23, 2018
Production, quality control, stability, and potency of cGMP-produced <i>Plasmodium falciparum</i> RH5.1 protein vaccine expressed in <i>Drosophila</i> S2 cellsJing Jin, Richard D Tarrant, Emma J Bolam, et al.
Pageof 7